Back to Learn
TesamorelinGuide2 min read

Tesamorelin and EGRIFTA: Approved Use vs. General Weight Loss

EGRIFTA WR contains tesamorelin and is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label states that it is not indicated for weight-loss management.

By PacificRx editorial team · Published

At a glance

EGRIFTA WR contains tesamorelin and is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its label states that it is not indicated for weight-loss management. That specific indication should not be generalized to ordinary weight loss or every body-composition goal.

  • An approved indication describes a specific clinical context.
  • Abdominal-fat outcomes are not the same as general weight loss.
  • A compounded preparation does not share an approved product's status.
This article is educational and is not medical advice. A licensed clinician must review your medical history before determining whether treatment is appropriate.Read our editorial standards.

What does the approved indication establish?

The EGRIFTA WR label describes a growth hormone-releasing factor analog for excess abdominal fat in adults with HIV-associated lipodystrophy. The population and condition are part of the indication; they should not disappear when the product is summarized in a marketing claim.

The label also includes limitations, including that the product is not indicated for weight-loss management. A phrase such as belly-fat treatment, without the clinical context, can therefore leave an inaccurate impression.

How should I compare claims?

Identify whether a claim concerns the approved product, a particular clinical study, an off-label proposal, or a compounded preparation. These are different contexts with different evidence and regulatory questions.

A finding involving a specific study population does not establish the same benefit for every adult seeking a body-composition change. Ask what outcome was measured and whether the evidence applies to your actual goal and circumstances.

What should a consultation clarify?

Discuss the exact product, clinical rationale, medical history, alternatives, potential harms, and monitoring. A clinician should explain both what is known and what remains uncertain for any proposed use.

Compounded tesamorelin is not an FDA-approved generic or automatically equivalent to an EGRIFTA product. Confirm which formulation's instructions govern the actual prescription instead of borrowing directions from an approved brand with a different presentation.

Sources